Hybrid AI-Machine Learning and Quantum-Enhanced Predictive System for Early Cancer Detection and Personalized Health Risk Assessment

Abstract

Cancer remains one of the leading causes of mortality worldwide, and its early detection plays a critical role in improving patient survival rates and treatment outcomes. Traditional diagnostic methods, while effective, often face limitations such as high cost, delayed detection, and dependency on expert evaluation. Recent advancements in Artificial Intelligence (AI) and Machine Learning (ML) have opened new possibilities for enhancing cancer diagnosis, prediction, and prognosis. These technologies enable automated data analysis, uncover hidden patterns, and support clinical decision- making with higher accuracy and efficiency. This study explores various AI and ML approaches applied in early cancer detection and prognosis, focusing on supervised learning, deep learning, and ensemble techniques. The integration of algorithms with medical imaging, genomic data, and electronic health records has demonstrated remarkable improvements in identifying cancer at early stages. Deep learning models, particularly convolutional neural networks, have shown promising results in analyzing histopathological and radiological images. Similarly, machine learning algorithms such as Support Vector Machines, Random Forests, and Gradient Boosting have been effective in predicting cancer risk factors and survival rates. The abstract also highlights challenges associated with AI adoption in healthcare, including data privacy, model interpretability, and the need for large, high-quality datasets. Despite these challenges, AI- driven solutions hold immense potential to complement traditional diagnostic practices and advance personalized medicine. Future research should focus on explainable AI, robust validation frameworks, and collaborative systems that bridge the gap between data scientists and medical professionals.

Introduction

Cancer remains a leading global health challenge, with early detection being critical to improving survival rates. Traditional diagnostic methods like biopsies, imaging, and lab tests, while essential, face limitations such as high cost, delayed results, subjectivity, and limited accessibility. In response, Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative tools in oncology, capable of analyzing large-scale clinical, imaging, and genomic data to detect subtle patterns and predict disease progression. Techniques such as Support Vector Machines, Random Forests, and Convolutional Neural Networks (CNNs) have shown high accuracy in early cancer detection and prognosis.

Prior research has demonstrated AI’s effectiveness in multi-modal cancer data analysis, including imaging, genomics, and clinical records, while also highlighting challenges related to interpretability, data scarcity, and ethical concerns. The proposed system introduces an intelligent AI/ML framework that integrates heterogeneous datasets, applies preprocessing and feature extraction, and employs both machine learning and deep learning models to provide real-time risk prediction, tumor classification, and survival prognosis.

Evaluation results show that the system outperforms traditional methods in speed, accuracy, and consistency, with CNNs achieving over 94% accuracy on imaging data and ensemble ML models performing well on structured clinical and genomic data. Multi-modal integration further improves predictive performance, while explainable AI techniques (e.g., Grad-CAM, SHAP) enhance transparency and clinical trust. Overall, the framework offers a scalable, interpretable, and clinically relevant solution for early cancer detection, prognosis, and personalized treatment planning.

Conclusion

Cancer remains one of the most critical global health challenges, and its early detection is essential for reducing mortality and improving patient outcomes. Traditional diagnostic methods, though reliable, often suffer from limitations such as high costs, dependency on clinical expertise, and late detection. This study reviewed how Artificial Intelligence (AI) and Machine Learning (ML) approaches can address these challenges by offering data-driven, automated, and scalable solutions for cancer detection and prognosis. The review of related work highlighted that supervised learning algorithms, including Support Vector Machines, Random Forests, and Logistic Regression, have been successfully applied to predict cancer risk factors and survival rates. Similarly, deep learning techniques, particularly Convolutional Neural Networks, have demonstrated exceptional accuracy in analyzing medical imaging data such as MRI, CT, and histopathology images. These advancements prove that AI and ML models can identify subtle patterns that may go unnoticed by human experts, thereby enabling earlier and more precise diagnoses. Despite their promise, several challenges remain. Issues such as data imbalance, privacy concerns, model interpretability, and the need for large, high-quality datasets continue to limit the clinical adoption of AI solutions. Furthermore, the“black-box” nature of many deep learning models raises concerns among healthcare professionals regarding trust and transparency. Addressing these limitations through explainable AI, stronger validation frameworks, and collaborative approaches between data scientists and clinicians is crucial for real-world implementation. In conclusion, AI and ML are revolutionizing the way cancer is detected and managed. Their integration into clinical workflows has the potential to significantly enhance diagnosis, support personalized treatment strategies, and improve patient survival. Future research should focus on making these models more explainable, ethical, and universally accessible, ensuring that the benefits of AI-driven cancer care reach patients worldwide.

References

[1] Esteva, et al.,“Aguide to deep learning in healthcare,” Nature Medicine, vol. 25, no. 1, pp.24-29, 2019, doi:10.1038/s41591-018-0316-z. [2] K. Kourou, et al., “Machine learning applications in cancer prognosis and prediction,” Computational and Structural Biotechnology Journal, vol. 13, pp. 8–17, 2015, doi: 10.1016/j.csbj.2014.11.005. [3] X. Li, et al., “Deep learning for cancer diagnosis and prognosis across multiple data modalities: A review,”Cancers, vol. 14, no. 2, p. 381, 2022, doi: 10.3390/cancers14020381. [4] J. A. Cruz and D. S. Wishart, “Applications of machine learning in cancer prediction and prognosis,” Cancer Informatics, vol. 2, pp. 59–77, 2007, doi: 10.1177/117693510700200030. [5] A. Sharma, et al., “Explainable artificial intelligence applications in cancer diagnosis and prognosis,” Diagnostics, vol. 13, no. 4, p. 743, 2023, doi: 10.3390/diagnostics13040743. [6] A. Hosny, et al., “Artificial intelligence vol. 13, no. 4, p. 743, 2023, doi: 10.3390/diagnostics13040743. [7] ZA. Hosny, et al., “Artificial intelligence in radiology,” Nature Reviews Cancer, vol. 18, no. 8, pp. 500–510, 2018, doi: 10.1038/s41568-018-0016-5. [8] K. Bera, et al., “Artificial intelligence in digital pathology—new tools for precision oncology,” Nature Reviews Clinical Oncology, vol. 16, no. 11, pp. 703–715, 2019, doi: 10.1038/s41571-019-0252-y. [9] J. E. Bibault, et al., “Artificial intelligence in cancer care: Applications and challenges,” CA: A Cancer Journal for Clinicians, vol. 69, no. 5, pp. 357–377, 2019, doi: 10.3322/caac.21552. [10] T. Ching, et al., “Opportunities and obstacles for deep learning in biology and medicine,” Journal of the Royal Society Interface, vol. 15, no. 141, p. 20170387, 2018, doi: 10.1098/rsif.2017.0387. [11] P. Tiwari, et al., “Machine learning in oncology: A review,” IEEE Reviews in Biomedical Engineering, vol. 16, pp. 128–147, 2023, doi: 10.1109/RBME.2023.3237659. [12] S. Rathore, et al., “Machine learning in cancer prognosis and prediction: A systematic review,” Computers in Biology and Medicine, vol. 145, p. 105383, 2022, doi: 10.1016/j.compbiomed.2022.105383. [13] M. M. Badža and M. Barjaktarovi?, “Classification of brain tumors from MRI images using a convolutional neural network,” Applied Sciences, vol. 10, no. 6, p. 1999, 2020, doi: 10.3390/app10061999. [14] Z. N. K. Swati, et al., “Content-based brain tumor retrieval for MR images using deep CNNs,” Neurocomputing, vol. 364, pp. 320–336, 2019, doi: 10.1016/j.neucom.2019.07.006. [15] K. H. Yu, et al., “Artificial intelligence in healthcare,” Nature Biomedical Engineering, vol. 2, pp. 719–731, 2018, doi: 10.1038/s41551-018-0305-z. [16] M. van der Schaar, et al., “Artificial intelligence and machine learning in cancer: Progress and opportunities,”British Journal of Cancer, vol. 126, pp. 861–867, 2022, doi: 10.1038/s41416-021-01662-x.

Copyright

Copyright © 2026 G. Tirumala, V. S. Vamsee Krishna T. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.